Candida albicans hyphal-to-yeast transition

The **Candida albicans hyphal-to-yeast transition** refers to the reversible morphological change in *C. albicans* from unicellular budding yeast to filamentous hyphal forms. This transition is regulated by multiple environmental cues—including temperature, pH, nutrients, CO₂, and quorum-sensing molecules—and a complex transcriptional network. Hyphal morphogenesis is a critical virulence determinant: it facilitates tissue invasion, immune evasion, biofilm formation on surfaces, and escape from host immune cells. Many molecular pathways modulate this transition, involving transcription factors (e.g., Efg1, Cph1, Ume6, Brg1), signaling cascades (cAMP/PKA, MAPK), and chromatin remodelers (HIR complex)[1][2][5][6][7]. Mutants unable to complete this transition display markedly reduced virulence in animal models. Although no drugs currently target this process specifically, components of the regulatory network (such as certain transcription factors or epigenetic regulators) are being studied as possible antifungal targets[1][2][5][6][7]. This process is essential to pathogenicity but is not by itself a discrete target such as a receptor, channel, or enzyme. Rather, it is governed by a network of (potentially targetable) regulators. Therefore, the entry is *not* a valid molecular target; rather, regulators of this transition (e.g., Efg1 transcription factor, cAMP/PKA signaling) would be the structured entities to consider as true drug targets.

Other names

yeast-to-hypha transitionYHTyeast-hyphal morphogenesishyphal morphogenesis

Inhibition of cell wall synthesis (for drugs that reduce hyphal formation) Inhibition of ergosterol biosynthesis Modulation of transcriptional regulators that control morphogenetic switching (experimental)